Abstract

The following highlights key, current information for immunization providers on COVID-19 vaccines. The evidence on COVID-19 disease and vaccines is evolving. Evidence from clinical trial data is limited due to limitations in the size and duration of follow-up of trial populations; however, studies are ongoing. NACI will continue to monitor the data and update its recommendations as needed. Please refer to the remainder of the Statement for details.

  • Recommendation
  • Americas
  • Canada
  • Pfizer-BioNTech vaccine
  • Moderna COVID-19 vaccine
  • AstraZeneca COVID-19 vaccine
  • COVID-19